{"url_path":"/sec/cik-0000786947/8-k/2026-06-29/item-1-01","section_key":"item-1-01","section_title":"Item 1.01 Entry into a Material Definitive Agreement.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-29","source_url":"https://www.sec.gov/Archives/edgar/data/786947/0001104659-26-078839-index.html","accession_number":"0001104659-26-078839","cik":"0000786947","ticker":null,"issuer_name":"ACURA PHARMACEUTICALS, INC","edgar_url":"https://www.sec.gov/Archives/edgar/data/786947/0001104659-26-078839-index.html","primary_entity_key":"0000786947","primary_entity_name":"ACURA PHARMACEUTICALS, INC"},"word_count":384,"has_tables":true,"body_markdown":"**Item 1.01 – Entry into a Material Definitive Agreement.**\n\n \n\nWe previously announced on June 28, 2019,\nwe entered into a promissory note with John Schutte that consolidated existing promissory notes into a single note for $6.0 million bearing\ninterest at 7.5% (“$6.0 Million Note”). At that time, we also granted to Mr. Schutte conversion rights of the $6.0 Million\nNote into Acura common stock at $0.16 per share, issued to him a warrant to purchase 10.0 million shares of the Company’s common\nstock at a price of $0.01 per share having an expiration date of June 28, 2024 (“Warrant”) and granted a security interest\nin all our assets (“Security Agreement”). With our consent, effective on June 28, 2019, Mr. Schutte assigned and\ntransferred to AD Pharma all of his right, title and interest in this $6.0 Million Loan, Security Agreement and Warrant. We previously\nannounced on June 9, 2021, we received notice of conversion from AD Pharma for the $6.0 Million Note and approximately $877 thousand\nof accrued but unpaid interest on the $6.0 Million Note. The principal and interest on the $6.0 Million Note were converted into 42,984,375\nshares of the Company’s common stock.\n\n \n\n2\n\n \n\n \n\nEffective June 15, 2026, in consideration\nof further amending the November 10, 2022 Amended, Consolidated and Restated Secured Promissory Note (the “Note”) with\nAD Pharma which changed the maturity date of the Note from June 30, 2026 to December 31, 2026, we amended the Warrant to change\nthe expiration date of the Warrant from June 30, 2026 to December 31, 2026.\n\n \n\nThe inclusion of a description of the Warrant\nunder Item 1.01 of this Current Report on Form 8-K shall not be deemed an acknowledgement that the Note is a material agreement not\nmade, or deemed not to be made, in the ordinary course of our business.\n\n \n\nAt June 15, 2026, AD Pharma directly owns\napproximately 65% of the outstanding common stock of the Company. The ownership percentage of the Company held by AD Pharma does not include\ntheir warrant to purchase 10.0 million shares of common stock of the Company. AD Pharma is an entity controlled by Mr. Schutte, of\nwhich Mr. Schutte is the managing partner and investor. At June 15, 2026, Mr. Schutte directly owns approximately 13% of\nthe outstanding common stock of the Company."}